The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratory (U24 Clinical Trial Not Allowed)

Summary

The National Institutes of Health (NIH), specifically the National Cancer Institute (NCI), is soliciting applications for a Pharmacokinetic Resource Laboratory to support the Experimental Therapeutics Clinical Trials Network (ETCTN). The U24 cooperative agreement mechanism indicates a substantial resource-sharing or infrastructure support role. Clinical trials are explicitly excluded from the scope of this award. The laboratory is expected to provide pharmacokinetic (PK) analysis services and related scientific support to the ETCTN network.

What they want

How they evaluate

Risks & flags

• Highly specialized scope (PK Resource Laboratory for ETCTN) may favor incumbent or well-established academic/research laboratory already integrated into the ETCTN infrastructure
• U24 cooperative agreement mechanism is typically awarded to pre-identified resource centers, narrowing the competitive field
• No dollar value disclosed, limiting competitive intelligence for prospective applicants